Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms 1Neoplasm Metastasis 1Digestive System Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × NUC-1031 × Clear all
NCT04163900 2023-05-24

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

NuCana plc

Phase 3 Terminated
773 enrolled 15 charts
Gastrointestinal

Adenocarcinoma, Biliary Tract Neoplasms, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms, Cholangiocarcinoma

NCT03146663 2021-02-21

NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

NuCana plc

Phase 2 Terminated
53 enrolled 19 charts
Gynecologic

Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡